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Abstract
DNA repair pathway is considered to be one of the most important mechanisms 
that protect cells from intrinsic and extrinsic stresses. It has been established that 
DNA repair activity has a crucial role in the way that cancer cells respond to treat-
ment. Sarcomas are a group of tumors with mesenchymal origin in which their 
association with DNA repair aberrations has been reported in numerous studies. 
Special attention has been focused on exploiting these alterations to improve the 
patient’s overall survival and overcome drug resistance in cancer. While there is 
a large degree of heterogeneity among different types of sarcomas, DNA repair 
alteration is found to be a common defect in the majority of patients. In this chapter, 
we will introduce and review some of the most important dysregulated components 
involved in the DNA repair system, and discuss their association with tumorigen-
esis, cancer aggressiveness, drug resistance, and overall prognosis in the patients 
with sarcomas.
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1. Introduction
Sarcomas represent a divergent and heterogeneous group of malignancies 
comprising more than 70 subtypes, with a common characteristic of being 
derived from mesenchymal lineages such as bone, muscle, cartilage, and fat [1]. 
Sarcomas are rare, accounting for less than 1% of adult cancers and approximately 
15% of childhood malignancies [2]. They occur in all ages with an extensive 
intertumoral and intratumoral biological heterogeneity and widely varied clinical 
prognosis [3]. The primary standard of care approach for treatment of sarcoma 
patients is consist of surgery, radiation, and chemotherapy-based strategies [4]. 
Although the cure rate for the patients with localized sarcoma is generally more 
than 70%, the survival rate of metastatic and relapsed patients is still less than 
30% and has not been changed in the last decades [1, 2, 5, 6]. Based on the tis-
sue type of primary manifestation, sarcoma tumors could be categorized into 
two main groups: soft-tissue sarcomas (STS) and bone sarcomas. STS are more 
common with the incidence of approximately 13,000 reported cases versus 3000 
cases of bone sarcomas each year in the United States [4]. Among STS, liposar-
coma, leiomyosarcomas, and undifferentiated pleomorphic sarcomas are the most 
common types in adults, whereas rhabdomyosarcoma is the most common type 
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seen in pediatric age [7]. Osteosarcoma has the highest prevalence among bone 
sarcomas with a bimodal age distribution; an initial peak between the age of 10 
to 20 and a second peak in incidence above the age of 60 [8]. Based on genetic 
criteria sarcomas can also be classified into two main groups: sarcomas with low 
level of genomic alterations and fairly normal karyotypes, and sarcomas with high 
level of genomic alterations and complex karyotypes [5]. The sarcomas found in 
the first group have chromosomal translocations as illustrated in Table 1; whereas 
osteosarcoma, chondrosarcoma, and liposarcoma are more genetically complex 
and have broader range of dysregulations resulted from copy number variations, 
mutations, etc. (Table 1) [5, 9–11].
It is well established that DNA damage response (DDR) system has a major 
impact on prognosis and clinical response to treatment in cancer patients 
[12–14]. Studies have investigated the dysregulation of different DDR pathways 
in various types of sarcomas and provided possible prognostic and therapeutic 
potentials among DDR components in order to overcome drug resistance and 
improve overall survival of these patients. In this chapter, we review some of 
the most important dysregulated DDR components which are involved in five 
different pathways (base excision repair (BER), nucleotide excision repair 
(NER), DNA mismatch repair (MMR), homologous recombination (HR), Non-
homologous end joining (NHEJ), and DNA damage sensors (ATR and CHK1)) in 
sarcoma, and discuss the therapeutic developments and prognostic potentials in 
this area (Figure 1).





















Most common chromosomal aberrations in sarcomas.
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2. DNA repair machinery in Sarcoma
2.1 Base excision repair (BER) pathway
Base excision repair (BER) is a repair mechanism responsible for repairing 
single-strand DNA breaks (SSBs) or different types of damages including oxidiza-
tion, deamination, and alkylation on a single base that do not induce significant 
distortion to the DNA helix [15]. Among several proteins that are involved in this 
pathway, APE1/Ref-1 and Poly (ADP-ribose) polymerase (PARP) are considered as 
the most important players in cancer progression and drug resistance [16–19].
2.1.1 APE1/Ref-1
One of the most important components of BER pathway is APE1/Ref-1 
( apurinic/apyrimidinic endonuclease 1/redox factor-1). APE1/Ref-1 is a multi-
functional protein involved in response to oxidative stress, cell cycle regulation, 
transcriptional activation, protein stability, apoptosis, and cell survival [16, 20]. 
The different functions of this protein can be categorized into two main activities: 
apurinic/apyrimidinic endonuclease activity and reduction–oxidation (redox) 
activity. The endonuclease activity allows APE1/Ref-1 protein to function as a DDR 
component in BER pathway by recognizing and cleavage of the abasic site [21]. The 
redox activity of APE1/Ref-1 gives it a critical transcriptional regulatory role in 
which enhances the activity of numerous transcription factors, including STAT3, 
NF-kB, HIF-1, and AP-1 [21, 22]. APE1/Ref-1 has a crucial role in maintaining can-
cer cells in a survival state through its DNA repair properties [23, 24]. Also, its redox 
function increases the activity of signaling pathways that are involved in promoting 
growth, migration, and survival in tumor cells as well as inflammation and angio-
genesis in the tumor microenvironment [23, 25]. The overexpression of APE1/Ref-1 
has been reported in many tumor types, and that change is associated with drug 
resistance, metastasis, cancer aggressiveness, and overall poor prognosis [16].
Several studies have shown that APE1/Ref-1 protein is overexpressed in sar-
coma patients and is correlated with metastasis and lower survival rates [26–30]. 
Figure 1. 
Schematic summary of the most important DDR components and their respective inhibitors in sarcomas.
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The correlation between angiogenesis, as an important factor in tumor growth and 
metastasis, and APE1/Ref-1 in osteosarcoma was elucidated by the series of studies 
conducted by Wang et al. [26, 31–33]. They showed that transforming growth factor 
beta (TGFβ) is directly regulated by APE1/Ref-1 and its expression level was signifi-
cantly reduced in APE1/Ref-1 deficient osteosarcoma cells [31]. TGFβ increases the 
chances of cancer metastasis through multiple mechanisms including immunosup-
pression, invasion, and angiogenesis [34]. They demonstrated that knocking down 
APE1/Ref-1 using specific siRNA in osteosarcoma led to down-regulation of TGFβ 
expression and suppression of angiogenesis in vitro based on human umbilical vein 
endothelial cells (HUVECs) in transwell and matrigel tube formation assays [31]. In 
addition, siRNA-mediated silencing of APE1/Ref-1 significantly suppressed tumor 
growth in xenograft mice models [31]. These experimental data indicated that 
APE1/Ref-1 promotes angiogenesis in osteosarcoma through a TGFβ-dependent 
pathway [31]. Additionally, they showed that the expression levels of vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) are also 
regulated by APE1/Ref-1 [32]. However, the suppression of angiogenesis in APE1/
Ref-1 knockdown cells is not dependent on their transcriptional activity [32, 33]. 
Wang et al., also used siRNA against APE1/Ref-1 protein to investigate its inhibi-
tion in osteosarcoma [26]. They demonstrated that the siRNA-mediated inhibition 
of APE1/Ref-1 sensitized the osteosarcoma cells to DNA damaging agents: methyl 
methanesulfonate, H2O2, ionizing radiation, and chemotherapeutic agents [26]. 
Another study conducted by Xiao et al., investigated the association of APE1/Ref-1 
polymorphisms with osteosarcoma [35]. They performed a 2-stage case–control 
study in a total of 378 osteosarcoma patients and 616 normal controls and con-
cluded that the patients who have certain APE1/Ref-1 polymorphisms have lower 
APE1/Ref-1 expression and higher survival rates [35]. Over the past few years, small 
molecule inhibitors targeting APE1/Ref-1 have been developed and showed remark-
able anti-tumor effects with limited toxicity in a variety of cancers, in both in vitro 
and in vivo models [36–40]. However, the efficacy of these inhibitors still needs to 
be investigated in sarcomas.
2.1.2 PARP
Poly (ADP-ribose) polymerase (PARP) is another important DDR protein 
involved in cell proliferation, differentiation, and transformation [41]. PARP has 
the ability to covalently add poly ADP-ribose (PAR) chains to target proteins and 
alter their functions [42]. This enzymatic activity gives PARP the capability of being 
involved in diverse set of cellular processes including DNA damage repair [41, 42]. 
PARP inhibitors have drawn a lot of attention in cancer research community based 
on their remarkable anti-tumor effects in HR-deficient cancers [43]. Studies on 
PARP function in DNA repair system have led to development of numbers of FDA-
approved inhibitors for treatment of various solid tumors [44–46].
PARP protein is found to be playing a key role in sarcoma as well, highlighted by 
several preclinical and clinical studies conducted in recent years. A study designed 
by Park et al., underscored the association between PARP activity and poor progno-
sis in osteosarcoma patients and showed the efficacy of PARP inhibition in combi-
nation with chemotherapy in this disease [47]. They evaluated the expression level 
of DNA damage molecules in 35 osteosarcoma patients and found that the expres-
sion levels of PARP1, γH2AX, and The Breast Cancer Susceptibility genes (BRCA1 
and BRCA2) are accompanied with shorter overall survival in these patients [47]. 
In vitro experiments on osteosarcoma cell lines demonstrated that the PARP inhibi-
tor olaparib as a single agent could inhibit cell proliferation in a dose- and time-
dependent manner [47]. Moreover, the combination of olaparib with doxorubicin 
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showed significant synergistic effects in osteosarcoma cells [47]. The in vivo experi-
ments also validated the growth-suppressive effects of individual and co-treatment 
of olaparib and doxorubicin in orthotopic osteosarcoma mice models [47]. In 
osteosarcoma cells treated with the combination treatment of olaparib plus doxoru-
bicin, flow cytometry analysis showed increased apoptosis as evident by increased 
expression levels of cleaved caspase 3, cleaved PARP1, BAX, and decreased levels of 
BCL2 [47]. The sensitivity of HR-deficient osteosarcoma cells to PARP inhibition 
is demonstrated in a study performed by Engert et al. [48]. They treated a panel 
of osteosarcoma cell lines with PARP inhibitor talazoparib alone and in combina-
tion with chemotherapeutic drugs (temozolomide (TMZ), SN-38, doxorubicin, 
cisplatin, methotrexate (MTX), etoposide/carboplatin) [48]. They found a direct 
correlation between HR repair deficiency and increased sensitivity of osteosarcoma 
cells to PARP inhibition [48]. All osteosarcoma cell lines harboring BRCA1/2 muta-
tion for both alleles (so-called “BRCAness”) have shown a significant reduction 
in cell growth following treatment with talazoparib (MG63, ZK-58, Saos-2, and 
MNNG-HOS) [48]. However, U2OS (osteosarcoma cells) that are heterozygous for 
BRCA2 mutation and carry one intact allele were resistant to PARP inhibition [48]. 
Furthermore, TMZ showed the highest anti-proliferative synergistic effect with 
the PARP inhibitor among other chemotherapeutic drugs, and this effect induced 
through apoptosis pathway as indicated by caspase activation, increased expression 
level of BAX and BAK, DNA fragmentation, and loss of mitochondrial membrane 
potential [48]. These findings suggested a promising potential for development 
of novel therapeutic strategies using PARP inhibitors in combination with con-
ventional treatments in osteosarcoma patients with features of BRCAness (more 
discussed in Section 3.4.1). Likewise, a large number of preclinical studies on other 
types of sarcomas including Ewing sarcoma, chondrosarcoma, rhabdomyosarcoma, 
and other STS emphasized the effectiveness of PARP inhibition in combination 
with chemotherapy as a promising therapeutic strategy for treatment of sarcoma 
patients [49–53]. In a study conducted by Laroche et al., the anti-tumor effect of 
PARP inhibitor rucaparib in combination with a chemotherapy drug trabectedin 
was explored in a panel of STS cell lines and a mouse model of liposarcoma [54]. 
The data obtained from this study demonstrated that the combination of rucaparib 
and trabectedin synergistically inhibited cell growth and induced G2M cell cycle 
arrest, γH2AX intranuclear accumulation, and apoptosis in vitro [54]. They also 
carried out in vivo experiments and showed that this combination significantly 
suppressed tumor growth, increased the progression-free survival, and elevated the 
percentage of tumor necrosis in the xenograft mice model [54].
Although preclinical studies have presented PARP inhibition as an effective 
treatment option in sarcoma, clinical trials have failed to demonstrate a promising 
clinical outcome in patients so far [55, 56]. Schafer et al. conducted a phase I/II 
clinical trial of PARP inhibitor talazoparib in combination with low-dose temo-
zolomide in patients with refractory/recurrent solid tumors including sarcoma 
[55]. From April 2014 to January 2018, 40 patients (including 15 Ewing sarcoma, 
4 osteosarcomas, 2 synovial sarcomas, and one rhabdomyosarcoma) were enrolled 
in this study and treated with talazoparib and temozolomide [55]. The data showed 
that this combination therapy was well tolerated; reversible neutropenia and 
thrombocytopenia were the primary dose-limiting toxicities (DLTs) [55]. However, 
no significant anti-tumor activity was observed in sarcoma patients [55]. Similarly, 
a phase II clinical trial of PARP inhibitor (olaparib) in refractory Ewing sarcoma 
patients has also failed to demonstrate a promising clinical outcome [56]. One pos-
sible explanation for this direct contrast between preclinical and clinical studies is 
that PARP inhibition could induce anti-tumor effects in de novo Ewing sarcoma but 
not in pretreated, chemoresistant patients [55, 56]. However, the limited number of 
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completed clinical trials of PARP inhibitors in sarcoma compared to other tumors 
hinders us from making a definite conclusion (Table 2). Future preclinical and 
clinical studies will shed more lights on the effectiveness of PARP inhibition as a 
possible treatment approach for sarcoma patients.
2.2 Nucleotide excision repair (NER) pathway
NER is a DDR pathway responsible for repairing bulky DNA lesions induced 
by ultraviolet irradiation, carcinogens, and some chemotherapeutic agents such 
as cisplatin [57]. The involvement of NER pathway in DNA damage induced by 
chemotherapeutic drugs attracted researchers to investigate the association of NER 
activity with the response to these cytotoxic agents in various cancers. Although 
there are some controversies regarding the role of NER pathway in cancer, some 
studies showed direct correlations between NER activity and increased response 
to chemotherapy [15, 57]. Recent efforts in whole-genome sequencing and data 
analysis of The Cancer Genome Atlas have led to a better understanding of the roles 
of the molecules involved in this pathway and introduced NER genes as prognostic 
biomarkers of response to various DNA damaging chemotherapeutic in different 
types of cancers [15, 57–60].
2.2.1 ERCC1
ERCC1 is the key component of NER pathway that has been investigated in 
a large number of studies due to its prognostic properties in cancer treatment 
[61–63]. The association between the expression of ERCC1 and response to trabect-
edin in STS was investigated in a recent translational study designed by Moura et al. 
[64]. Expression levels were evaluated using qRT-PCR in 66 patients with advanced 
STS who were treated with trabectedin. The results showed that the expression 
level of ERCC1 is correlated with patients’ progression-free survival [PFS (the 
length of time during and after treatment that the disease does not get worse)] 
and overall survival. Patients who had higher expression levels of ERCC1 showed 
better responses to the trabectedin and had longer PFS rates [64]. Similarly, ERCC1 
expression has reported to be associated with treatment response in other sarcomas 
such as osteosarcoma and leiomyosarcoma, highlighting the importance of this 
key NER protein as a predictable biomarker in sarcoma [65, 66]. Polymorphism of 
NER genes and the relation of different alleles with the treatment response has also 
been investigated in osteosarcoma, indicating the association of some polymor-
phisms with a higher risk of osteosarcoma development [67]. A study conducted 
by Obiedat et al., investigated the relationship between polymorphisms of ERCC1 
and ERCC2 and response to cisplatin-based chemotherapy and clinical outcomes 
in osteosarcoma patients [68]. They analyzed the association between ERCC1 
Compound Phase Cancer type and trial details Clinical trail identifier
Olaparib II Adult participants with recurrent/metastatic 
Ewing sarcoma
NCT01583543
Talazoparib I Advanced or recurrent solid tumors 
(including Ewing sarcoma)
NCT01286987




Sarcoma clinical trials of PARP inhibitors.
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(C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and 
G312A (rs1799793)) polymorphisms and clinical parameters including event-free 
survival (EFS) (the length of time after treatment that a patient lives without any 
complications or event that the treatment intended to prevent or delay) rates in 
44 patients with osteosarcoma who were treated with cisplatin-based neoadjuvant 
chemotherapy [68]. The findings illustrated that there is a significant positive corre-
lation between ERCC1 C8092 A genotypes and median EFS rate. In other words, the 
patients who carried allele C (CC & CA) had longer EFS rates than patients with AA 
genotype, highlighting the importance of ERCC1 polymorphism in osteosarcoma 
[68]. Taken together, these studies suggested that ERCC1 could be considered as a 
reliable predictive factor of the effectiveness of some DNA-damaging chemothera-
peutic drugs in sarcoma patients, and different polymorphisms could be used as 
prognostic biomarkers for designing the best treatment strategy.
2.3 DNA mismatch repair (MMR) pathway
2.3.1 MSH2-MSH6 (MutSα)
MMR pathway is responsible for repairing base mismatches, insertions and dele-
tions arise from DNA replication, genomic recombination, and other error-prone 
DNA repair systems [69]. MSH2-MSH6 (MutSα) complex plays an important role in 
this pathway by recognizing the mismatched bases and starting the MMR process 
[69]. Different polymorphisms and expression levels of MMR components have 
shown to be associated with prognosis and survival in cancer patients [70–72].
A study conducted by Li et al., emphasized the importance of MMR pathway 
in Ewing sarcoma and showed that the expression levels of MSH2 and MSH6 is 
correlated with an increased chance of metastasis and poor prognosis in these 
patients [73]. They used the GEO database to investigate the correlation of the key 
dysregulated genes and pathways with prognosis information and metastasis status 
of the Ewing sarcoma patients [73]. The findings highlighted the MMR pathway as 
the most significantly enriched KEGG pathway in EWS patients [73]. The expression 
levels of key MMR components including MSH2 and MSH6 are found to be signifi-
cantly associated with metastasis, shorter EFS, and overall poor prognosis in Ewing 
sarcoma patients [73]. Several studies have investigated the role of MMR pathway 
in osteosarcoma. Liu et al., investigated the growth-suppressive effects of MSH6 
gene silencing in combination with cisplatin in osteosarcoma [74]. Microarray-based 
gene expression analysis of samples obtained from 67 osteosarcoma patients along 
with 24 normal patients demonstrated that MSH6 is significantly up-regulated in 
osteosarcoma patients [74]. Then, they evaluated cell proliferation, cell cycle distri-
bution, gene and protein expression, and apoptosis of osteosarcoma cell line MG63 
after co-treatment with cisplatin and siRNA targeting MSH6 [74]. The data showed 
that silencing MSH6 in combination with cisplatin reduced expression levels c-Myc, 
cyclin D1, Bcl-2, Stathmin, and PCNA and increased BAX expression in osteosarcoma 
cells [74]. This combination treatment also induced significant anti-proliferative 
effects, indicating that MSH6 could be considered as a potential therapeutic target 
for treatment of osteosarcoma patients [74]. In another study, proteomic analysis 
for identification of proteins that are differentially expressed between osteosarcoma 
and normal osteoblastic cells revealed that chromosome segregation 1-like (CSE1L) 
protein is significantly associated with the growth of osteosarcoma cells [75]. 
Co-immunoprecipitation and RNA-seq analysis in this study showed that CSE1L acts 
as a positive regulator of MSH6 in osteosarcoma cells [75]. In addition, they knocked 
down CSE1L protein in osteosarcoma cells and found significant growth suppression 
[75]. Furthermore, to investigate the role of MSH6, they overexpressed MSH6 in 
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CSE1L-knockdown osteosarcoma cells [75]. The results showed that overexpression 
of MSH6 significantly increased cell proliferation rate and reversed the anti-tumor 
effects observed in CSE1L-knockdown cells, indicating that CSE1L activity is depen-
dent on MSH6 expression [75]. Moreover, down-regulation of MSH6 resulted in 
suppression of cell growth in both in vitro and in vivo experiments [75]. The prognos-
tic potential of MSH6 and CSE1L was also explored by evaluation of the MSH6 and 
CSE1L expression levels in tumor samples [75]. They found a significant correlation 
between the expression of these two proteins and overall poor prognosis in osteosar-
coma patients [75]. Similarly, another study on osteosarcoma patients showed that 
overexpression of MSH2 and MSH6 is significantly associated with shorter survival 
time, lower sensitivity to chemotherapy, and higher chances of metastasis [76]. These 
studies underscored the significance of MMR proteins as both prognostic biomarkers 
and possible therapeutic targets in sarcoma.
2.4 Homologous recombination (HR) pathway
2.4.1 BRCA1/BRCA2
HR is the major DDR mechanism responsible for repairing double-strand DNA 
breaks (DBSs) [69]. HR repairs DSBs in an error-free manner by using homologous 
sequence of sister chromatid as an undamaged template [15]. BRCA1, BRCA2 and 
RAD51 are the key factors involved in this DDR pathway which have shown to be 
dysregulated in various types of cancers [15, 77–79]. Inherited mutations of the 
BRCA genes predispose individuals to develop tumors in various organs including 
breast and ovary [80]. Moreover, the chance of developing cancer significantly 
increases by acquiring BRCA mutations, and these mutations are commonly seen 
in patients with breast and ovarian cancers [80]. However, it has been reported 
that BRCA mutation has potential for inducing synthetic lethality in the cancer 
cells [81]. PARP inhibition in BRCA-mutated cancer cells (HR-deficient) induces 
synthetic lethality and cell death and provides a promising opportunity to eliminate 
cancerous cells (Figure 2). Several PARP inhibitors have been approved as mono-
therapies in HR-deficient ovarian and metastatic breast cancers [81].
As we discussed earlier in this chapter (Section 3.1.2), studies on osteosar-
coma demonstrated that BRCA is frequently mutated in osteosarcoma and PARP 
inhibition either as a monotherapy or in combination with chemotherapy could 
induce significant anti-tumor effects in BRCA-mutated osteosarcoma cells [48, 
82]. Although the significance of BRCA mutation status as a prognostic factor in 
sarcoma has been reported in a numerous studies [83–85], more clinical trials are 
warranted to determine the efficacy of PARP inhibitors in BRCA-mutated sarcomas. 
The importance of BRCA status in sensitivity to the chemotherapeutic drug trabect-
edin in STS is emphasized in a review paper gathered by Monk et al., and presented 
that BRCA mutations are significantly associated with favorable clinical response to 
trabectedin [83]. The frequency of BRCA mutation in soft-tissue sarcoma though, 
has not found to be significantly high in a study conducted by Seligson et al. [86]. 
They performed DNA sequencing analysis on 1236 STS patients as well as an 
additional 1312 leiomyosarcoma patients [86]. The unselected STS analysis revealed 
that only 1% of patients had BRCA2 mutation [86]. However, subset analysis 
showed that BRCA2 mutation could be found in 10% of leiomyosarcoma patients 
[86]. The frequency of BRCA1 mutation was not significant in either analysis [86]. 
Furthermore, they showed that PARP inhibition demonstrates effective clinical 
outcomes in BRCA2 deficient leiomyosarcoma patients [86]. Consistently, another 
study demonstrated a significant correlation between the overexpression of BRCA1, 
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BRCA2, PARP, and γH2AX and higher tumor stage, higher chances of metastasis, 
lower survival rates, and overall poor prognosis in STS patients [87]. These studies 
highlighted the significance of BRCA status in sarcoma and underscored the fact 
that HR mutations should be considered as predictive factors for increasing the 
overall survival of patients by choosing the best treatment strategy.
2.4.2 RAD51
RAD51 is another key protein in the HR pathway that is also associated with 
prognosis and treatment response in various cancers. A growing number of studies 
demonstrate that RAD51 protein is overexpressed in many cancers including breast, 
prostate, bladder, pancreas, and lung, and this overexpression can up-regulate HR 
activity and result in resistance to DNA-damaging drugs [88–91]. Increased expres-
sion of RAD51 has also been reported in sarcoma patients [92, 93]. Du et al. con-
ducted a study to explore the relationship between RAD51 expression and resistance 
to radio- or chemotherapy in osteosarcoma [93]. They suppressed the expression of 
RAD51 using shRNA and found increased sensitivity to chemotherapy and radia-
tion in osteosarcoma cell lines through induction of cell cycle arrest and apoptosis 
[93]. Hannay et al., investigated the association between RAD51 expression and 
resistance to chemotherapy in STS patients [92]. They evaluated the RAD51 expres-
sion in 62 human primary recurrent and metastatic STS samples [92]. Only 3 tumor 
samples showed no RAD51 expression, while most of them had overexpressed 
RAD51 expression levels [92]. They showed that siRNA-mediated RAD51 targeting 
resulted in STS sensitivity to doxorubicin [92]. Overall, these studies highlighted 
the significance of RAD51 in chemoresistance and suggested that RAD51 could 
be considered as a prognostic factor or even a therapeutic target for treatment of 
sarcoma patients.
Figure 2. 
Schematic role of PARP and PARP inhibition in synthetic lethality. (A) After binding to damaged DNA, PARP 
undergoes conformational change and poly(ADP-ribosyl)ation which results in recruitment of other DNA 
Damage Response (DDR) proteins, like DNA ligase 3 (Lig3), DNA polymerase β (polβ) and X-ray repair 
cross-complementing protein 1 (XRCC1), leading to DNA repair and cell survival. (B) PARP inhibitors block 
PARP activity, leading to double-strand break (DSB). The cells that have normal homologous recombination 
(HR) pathway are able to repair the DSBs in a error-free manner, leading to cell survival. However, BRCA-mutated 
cancer cells (HR-deficient) are unable to efficiently repair DSBs which ultimately results in cell death.
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2.5 Non-homologous end joining (NHEJ) pathway
The NHEJ pathway is another important pathway responsible for repairing DSBs 
[94]. Unlike HR, NHEJ directly re-ligates two broken DNA strands without requir-
ing a homologous sequence as an undamaged template, which makes this pathway 
prone to making errors [94]. NHEJ is initiated by binding of KU70/80 proteins, fol-
lowed by recruitment of other key factors such as DNA-dependent protein kinases 
(DNA-PKcs), XRCC4, XLF, LIG4, and PAXX (a newly identified NHEJ component) 
[95] to complete the repair process [96]. Loss of the key factors involved in this 
pathway is positively correlated with increased genomic instability and sensitivity 
to DNA damaging chemotherapy drugs [94]. However, the over-activation of NHEJ 
has also been reported to be associated with increased genomic instability and 
tumorigenesis due to error-prone and inappropriate repair [94]. Thereby, both loss 
and over-activation of NHEJ factors have found to be associated with increased can-
cer incidence [94]. Moreover, a large number of studies have shown that differential 
expression of key NHEJ factors has significant impacts on the treatment response 
and overall prognosis in different types of cancers [94, 97–101].
Several studies have shown the significance of NHEJ components in sarcomas. 
For example, in a study on Ewing sarcoma patients, Kyriazoglou et al., has reported 
that NHEJ and HR genes are significantly up-regulated in comparison with healthy 
blood donors [102]. They analyzed the expression levels of 15 genes in 32 cases 
of Ewing sarcoma using Real-time PCR. XRCC5, XRCC6, Polm, LIG4 from the 
NHEJ pathway and RAD51, RAD52, RAD54, BRCA2, and FRANCD from the HR 
pathways have found to be significantly up-regulated in Ewing sarcoma patients 
[102]. In another study, Ma et al. investigated the role of PAXX protein in chemore-
sistance in osteosarcoma [96]. They found a significant positive correlation between 
enhanced PAXX-KU70 interaction and NHEJ efficiency and resistance to doxo-
rubicin and cisplatin [96]. They also showed that PAXX deficiency re-sensitizes 
osteosarcoma cells to the chemotherapy drugs, which provides evidence that PAXX 
protein could be considered as a target for treatment of chemoresistant osteosar-
coma patients [96]. Additionally study conducted by Hu et al., demonstrated the 
significance of KU80 expression in radiosensitivity of osteosarcoma cells [103]. 
They have shown that shRNA-mediated suppression of KU80 protein sensitized 
U2OS osteosarcoma cells to radiation through shortening of telomere length [103]. 
Taken together, key NHEJ factors have important roles in cancer progression, 
drug resistance, and patient’s prognosis [94], which makes them interesting for 
further research regarding their prognostic and therapeutic potential in sarcomas. 
However, targeting NHEJ remains challenging as little is known about the inhibi-
tors. Several PI3K inhibitors such as wortmannin and LY94002 (Figure 1) are being 
used for therapeutic intervention of DNA-PKcs in the NHEJ pathway [104].
2.6 ATR/CHK1 DNA damage sensors in DNA repair pathways
2.6.1 ATR
Ataxia-telangiectasia and Rad3-related protein (ATR) is one of the most 
upstream DDR kinases and belongs to the phosphatidylinositol 3-kinase-related 
kinase (PIKK) protein family [105]. ATR is a serine/threonine-protein kinase acti-
vated in response to a broad spectrum of DNA damage, including DSBs and various 
DNA lesions that interfere with replication [106]. In response to DNA damage, 
several proteins are phosphorylated at Ser/Thr-Glu motifs and additional sites in 
response to DNA damage by ATR [107]. ATR phosphorylates its major downstream 
effector checkpoint kinase 1 (CHK1) and prevents the entry of cells with damaged 
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or incompletely replicated DNA into mitosis from the G2 phase of the cell cycle 
[108]. This regulation is particularly apparent in cells with a defective G1 check-
point, a common cancer cell feature because of p53 mutations [109, 110]. ATR also 
suppresses replication stress (RS) by inhibition of extra origin firing, particularly in 
cells with activated oncogenes [111]. Therefore, ATR could be an ideal therapeutic 
target in cancer. Currently, ATR inhibitors have been developed and are used either 
as single agents or in combination with radiotherapy or chemotherapy in both 
preclinical and clinical studies [112].
Several preclinical studies demonstrate that ATR could be a therapeutic target in 
sarcomas [113–117]. Laroche-clary et al., designed a study to investigate the anti-
tumor effects of ATR inhibition in STS [113]. They treated STS cell lines with ATR 
inhibitor VE-822 either as a single agent or in combination with gemcitabine as a 
chemotherapeutic drug [113]. The data demonstrated significant synergist effects 
between these two drugs [113]. They found considerable cell growth suppression, 
apoptosis induction, and increased γH2AX expression after combined treatment 
of STS cells with VE-822 and gemcitabine in a higher efficacy than either agent 
alone [113]. Furthermore, they performed in vivo experiments on a patient-derived 
xenografts (PDXs) of undifferentiated pleomorphic sarcoma and found significant 
tumor growth suppression and increased PFS after treatment with combination of 
VE-822 and gemcitabine [113]. Taken together, this study highlighted the impor-
tance of ATR in STS and showed that ATR inhibition in combination with chemo-
therapy is efficacious in pre-clinical models. In another study, a series of parallel 
high-throughput siRNA screens were performed by Jones et al., in synovial sarcoma 
tumor cells and the results were compared with more than 130 non-synovial 
sarcoma tumor cells to get better insights into genetic dependencies and potential 
therapeutic targets in synovial sarcoma [114]. The analysis revealed a significant 
reliance of synovial sarcoma tumor cells on ATR protein kinase activity [114]. 
Furthermore, they showed that ATR inhibition will result in significant anti-tumor 
effects in synovial sarcoma in vitro and in vivo [114]. They also performed com-
bination treatments with cisplatin and PARP inhibitors and found higher tumor-
suppressive effects than either agent alone [114]. In summary, this study presented 
ATR protein alteration as a key factor in synovial sarcoma progression and proposed 
a novel therapeutic potential for synovial sarcoma patients [114]. The role of ATR 
protein was also demonstrated in Ewing sarcoma [115]. Nieto-Soler et al., designed 
a study to investigate the importance of ATR pathway in Ewing sarcoma [115]. They 
showed that Ewing sarcoma tumors that have high levels of RS are significantly 
dependent on ATR pathway [115]. Furthermore, they treated Ewing sarcoma cell 
lines and mice models with two independent ATR inhibitors and found considerable 
anti-tumor effects both in vitro and in vivo [115]. Collectively, this study highlighted 
the dependency of Ewing sarcoma to ATR pathway and identified ATR inhibition 
as a promising therapeutic strategy in Ewing sarcoma with high levels of RS [115]. 
Future preclinical studies and subsequent clinical trials will provide with addi-
tional reliable data on the effectiveness of ATR inhibition in sarcoma to translate 
this therapeutic approach into clinic as a possible treatment approach for sarcoma 
patients.
2.6.2 CHK1
As mentioned above, checkpoint kinase 1 (CHK1) is the major downstream 
effector of ATR [108]. CHK1, a serine/threonine-specific protein kinase, plays an 
essential role in preventing cell cycle progression when damaged DNA is being 
repaired [118, 119]. DNA damage is sensed by ATR, activated ATR phosphorylates 
and activates CHK1. CHK1 has several targets which all act to regulate cell cycle 
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arrest [118]. Phosphorylation of the CDC25 dual specificity phosphatase family 
mediated by CHK1 causes phosphatase degradation, resulting in increased phos-
phorylation and inhibition of multiple cyclin dependent kinase (CDK) proteins, 
positive regulators of the cell cycle [119]. In addition to CDC25 phosphatases, 
WEE1 kinase is phosphorylated and activated by CHK1, subsequently leading to the 
inhibitory phosphorylation of CDK1 [120]. It is therefore logical that inhibitors of 
CHK1 in cancer treatment could facilitate cell cycle progression with damaged DNA 
and induce apoptosis [118].
Several preclinical studies and a few clinical studies demonstrate that CHK1 
could be a therapeutic target in sarcoma treatment [115, 116, 121–124]. Laroche-
clary et al., conducted a study to investigate the role of CHK1 protein kinase in p53-
mutant and wild-type STS [122]. They performed a systematic screening of a panel 
of 10 STS cell lines after combination treatment of CHK1 inhibitor (GDC-0575) 
with gemcitabine [122]. They showed that GDC-0575 induced apoptosis by abrogat-
ing DNA damage-induced S and G2–M checkpoints [122]. Moreover, they observed 
a synergistic or additive effect of GDC-0575 in combination with gemcitabine in 
vitro and in vivo in TP53-proficient but not in TP53-deficient sarcoma models [122]. 
Before conducting the mentioned study, they had analyzed the expression profile of 
a series of 339 complex genomics sarcomas and 108 translocation-related sarcomas, 
they showed that CHK1 expression is significantly associated with poor prognosis 
in sarcoma patients [125]. Moreover, they evaluated the efficacy of CHK1 inhibition 
in STS patients in a phase 1 clinical study with 3 STS patients (two with p53 muta-
tion and one without p53 mutation) [122]. Two STS patients who had p53 mutation 
demonstrated promising response to the combination of gemcitabine and GDC-
0575, while the other patient displayed no clinical benefit [122]. In conclusion, they 
provided pre-clinical and clinical evidence of the significance of CHK1 activity in 
STS and revealed that combination of CHK1 inhibitors with chemotherapy could 
be a promising treatment strategy for p53-mutant STS patients [122, 125]. There are 
also numbers of studies which have highlighted the important role of CHK1 activity 
in osteosarcoma progression and drug resistance and showed that CHK1 inhibitors 
either as a single agent or in combination with other drugs could be considered as 
a promising therapeutic target for treatment of osteosarcoma patients [126–129]. 
Regarding the role of CHK1 in Ewing sarcoma progression, some studies demon-
strated that CHK1 protein is over-activated in Ewing sarcoma and showed that 
Ewing sarcoma cells are sensitive to CHK1 inhibitors either as a single agent or in 
combination with other drugs in vivo and in vitro [116, 121, 130, 131]. Further clini-
cal investigations are needed to confirm whether treatment of sarcoma with CHK1 
inhibition is efficacious therapeutic approach to improve sarcoma patient outcomes 
at a higher level of evidence.
3. Implications/conclusions
Collectively, the studies summarized in this chapter indicate that it will likely 
take more than just targeting a particular dysregulated DNA repair pathway in the 
context of chemotherapy to cure many relapsed and aggressive sarcomas. As men-
tioned above, targeting the dysregulated process of replication stress and genomic 
instability which promotes tumorigenicity in many cancers such as sarcoma is an 
area of intense interest [132]. The use of small molecule inhibitors that block not 
only DNA repair mechanisms but other global networks that may be connected to or 
independent of DNA repair mechanisms may be key to improving clinical outcomes. 
As such, our group used a systems biology approach to discover risk signatures and 
potential biomarkers of therapeutic response in pediatric adolescent and young 
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adults with aggressive osteosarcoma. We found that the MYC-RAD21 copy number 
gain correlated with poor overall survival and was a potential marker of replication 
stress. We demonstrated that an increase in replication stress via a combination 
therapy consisting of BET and CHK1 inhibitors in xenograft models of pediatric and 
AYA osteosarcomas that have copy number gains of MYC and RAD21, was effica-
cious and well tolerated [126]. Furthermore, to obtain insight into other potential 
treatments where DNA repair inhibitors can be combined, numerous efforts have 
focused on investigating and understanding of the cross-talk between the various 
DNA damage-repair pathways as well as with the tumor microenvironment so that 
novel therapeutic combinations can be identified [133]. For instance, it has reported 
that hypoxic conditions within the tumor microenvironment impairs the fidelity 
of DNA repair pathways [133]. Furthermore, increased immune response to tumor 
neoepitopes have been observed in cancer with impaired/dysregulated DNA repair 
pathways [133]. Therefore, preclinical and clinical validation of using DNA repair 
inhibitors in combination with anti-hypoxic or immunomodulatory therapies war-
rants additional investigation. Notably, DNA repair mechanisms clearly contribute 
to tumor resistance [134]. In fact, one mechanism, by which tumor resistance is 
regulated involves cancer stem cells (CSC) which have increased DNA repair capac-
ity [134]. Additionally, it has been reported that chromatin structure (euchromatin 
vs. heterochromatin) impacts the efficacy of DNA repair [135]. Thus, combination 
therapy targeting DNA repair pathways with agents targeting CSC or epigenetic 
proteins that regulate chromatin also require further evaluation. Several studies 
have shown associations between DNA repair pathways. With advancements in 
next-generation sequencing and use of precision genomics one clinical implication 
is that it may be possible to identify germline and/or somatic mutations involved in 
DNA repair proteins that could help delineate subsets of sarcoma patient-population 
that are predisposed to factors such as likelihood of getting the disease, onset of 
relapse/metastasis/recurrence, or possibility of therapeutic resistance to certain 
treatments [136]. Furthermore, within the patient population genetic polymor-
phisms associated with efficacy for DNA repair also become evident [137].
With progress in scientific technology, characterizing and profiling key compo-
nents of the repair pathways is now more feasible. This results in increased preclini-
cal validation studies using DNA repair inhibitors to improve therapeutic outcomes 
for otherwise therapeutically plateaued cancers like sarcomas. Development and 
implementation of novel therapeutic interventions involving DNA-repair proteins 
in combination with other targeted therapies and/or standard-of-care agents may 
help improve clinical outcomes in the patients. Furthermore, the role of DNA 
repair proteins and damaged cellular DNA are not only relevant in sarcomas but are 
pertinent to other cancers as well as contributing to the pathogenesis of many other 
diseases [138]. Therefore, identification of novel therapeutic combination involv-
ing DNA repair proteins is of high clinical value as it may be applicable for treating 
other human ailments.
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